居家粪便钙卫蛋白快速检测与ELISA监测炎症性肠病活动度结果的一致性
该单中心比较研究纳入荷兰101名10岁及以上参与者,于2015年6月至2016年10月居家用IBDoc快速检测粪便钙卫蛋白,并与Quantum Blue读取仪及ELISA法比对。IBDoc与Quantum Blue的Spearman相关系数为0.94,与ELISA为0.85;低浓度(<500 μg/g)时一致性较好,高浓度(≥500 μg/g)时一致性下降。作者认为高浓度结果需用其他方法确认。
要点
- IBDoc与Quantum Blue的Spearman相关系数为0.94,与ELISA为0.85。
- 钙卫蛋白<500 μg/g时,IBDoc与Quantum Blue 91%结果在±100 μg/g一致限内,与ELISA 71%一致。
- 钙卫蛋白≥500 μg/g时,IBDoc与Quantum Blue 81%结果在±200 μg/g一致限内,与ELISA 64%一致。
核心结论
- 居家侧向流法检测粪便钙卫蛋白与Quantum Blue及ELISA法结果一致,但仅限于浓度<500 μg/g时。
- 对于粪便钙卫蛋白浓度高于此水平的患者,IBDoc结果应由另一种方法确认。
研究设计与样本
- 单中心比较研究,纳入荷兰101名10岁及以上参与者,于2015年6月至2016年10月居家采集粪便样本进行IBDoc检测。
- 参与者将残留提取液和同一次排便的新鲜标本送至格罗宁根大学医学中心儿科与成人炎症性肠病中心,分别用Quantum Blue读取仪和ELISA法检测钙卫蛋白。
- 主要结局为IBDoc与Quantum Blue及ELISA结果的一致性,采用Bland-Altman图分析。
主要发现
- 共收到152份IBDoc结果、138份用于Quantum Blue分析的残留提取液样本和170份用于ELISA分析的新鲜粪便样本。
- IBDoc与Quantum Blue结果的Spearman秩相关系数为0.94,IBDoc与ELISA结果为0.85。
- 钙卫蛋白低浓度范围(<500 μg/g)时,91%的IBDoc-Quantum Blue结果在预设一致限(±100 μg/g)内,71%的IBDoc-ELISA结果一致。
- 钙卫蛋白高浓度范围(≥500 μg/g)时,81%的IBDoc-Quantum Blue结果在预设一致限(±200 μg/g)内,64%的IBDoc-ELISA结果一致。
临床怎么用
- 作者认为,居家侧向流法检测粪便钙卫蛋白在浓度<500 μg/g时与Quantum Blue和ELISA法结果一致。
- 作者认为,对于粪便钙卫蛋白浓度高于500 μg/g的患者,IBDoc结果应由另一种方法确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: An increasing number of physicians use repeated measurements of stool calprotectin to monitor intestinal inflammation in patients with inflammatory bowel diseases (IBDs). A lateral flow-based rapid test allows patients to measure their own stool calprotectin values at home. The test comes with a software application (IBDoc; Bühlmann Laboratories AG, Schönenbuch, Switzerland) that turns a smartphone camera into a results reader. We compared results from this method with those from the hospital-based reader (Quantum Blue; Bühlmann Laboratories AG) and enzyme-linked immunosorbent assay (ELISA) analysis. METHODS: In a single-center comparison study, we asked 101 participants (10 years of age or older) in the Netherlands to perform the IBDoc measurement on stool samples collected at home, from June 2015 to October 2016. Participants then sent the residual extraction fluid and a fresh specimen from the same bowel movement to our pediatric and adult IBD center at the University Medical Center Groningen, where the level of calprotectin was measured by the Quantum Blue reader and ELISA analysis, respectively. The primary outcome was the agreement of results between IBDoc and the Quantum Blue and ELISA analyses, determined by Bland-Altman plot analysis. RESULTS: We received 152 IBDoc results, 138 samples of residual extraction fluid for Quantum Blue analysis, and 170 fresh stool samples for ELISA analysis. Spearman's rank correlation coefficient was 0.94 for results obtained by IBDoc vs Quantum Blue and 0.85 for results obtained by IBDoc vs ELISA. At the low range of calprotectin level (<500 μg/g), 91% of IBDoc-Quantum Blue results were within the predefined limits of agreement (±100 μg/g), and 71% of IBDoc-ELISA results were in agreement. At the high range of calprotectin level (≥500 μg/g), 81% of IBDoc-Quantum Blue results were within the predefined limits of agreement (±200 μg/g) and 64% of IBDoc-ELISA results were in agreement. CONCLUSIONS: Measurements of fecal levels of calprotectin made with home-based lateral flow method were in agreement with measurements made by Quantum Blue and ELISA, as long as concentrations were <500 μg/g. For patients with concentrations of fecal calprotectin above this level, findings from IBDoc should be confirmed by another method. (Netherlands Trial Registration Number: NTR5133).
引用
- Heida A, Knol M, Kobold AM, et al. Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. Clin Gastroenterol Hepatol. 2017. PMID: 28606846. doi:10.1016/j.cgh.2017.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。